FutureChem Pharma

FutureChem is a leading South Korean biotechnology company focused on the development and commercialization of radiopharmaceuticals for both diagnostic and therapeutic applications. The company leverages its proprietary radioisotope labeling technologies to create theranostic solutions, primarily targeting oncology and neurodegenerative diseases. Its flagship therapeutic program, FC705, is a Lutetium-177 labeled PSMA-targeting agent for metastatic castration-resistant prostate cancer, currently undergoing Phase 2 clinical trials in the United States and South Korea. Additionally, FutureChem has successfully commercialized diagnostic agents for Alzheimer's and Parkinson's diseases, such as Florasul and PD-View. The company is publicly traded on the KOSDAQ exchange and maintains a strategic focus on expanding its global footprint through international clinical trials and licensing partnerships.